Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 27.91 is 45% above its 5-year average of 19.31, near the high end of its 5-year range (10.60–30.13).
1.33% below its 12-month average of 28.29.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 7.82.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:16:11.359Z. Historical observations retain their original dates. Historical series through 2026-09-09.
EARNINGS PER SHARE (EPS)
27.91
EARNINGS PER SHARE (EPS) AVG TTM
28.29
EARNINGS PER SHARE (EPS) AVG 3Y
23.40
EARNINGS PER SHARE (EPS) AVG 5Y
19.31
EARNINGS PER SHARE (EPS) AVG 10Y
15.18
EARNINGS PER SHARE (EPS) AVG 15Y
11.81
EARNINGS PER SHARE (EPS) AVG 20Y
9.14
CURRENT VS TTM AVG
-1.33%
CURRENT VS 3Y AVG
+19.29%
CURRENT VS 5Y AVG
+44.56%
CURRENT VS 10Y AVG
+83.89%
CURRENT VS 15Y AVG
+136.23%
CURRENT VS 20Y AVG
+205.28%
United Therapeutics Corporation
Market Cap
$21.10B
Earnings Per Share (EPS)
27.91
TTM Avg
28.29
3Y Avg
23.40
5Y Avg
19.31
Market Cap
$19.23B
Earnings Per Share (EPS)
-0.36
TTM Avg
-1.77
3Y Avg
-0.44
5Y Avg
-0.66
Market Cap
$18.09B
Earnings Per Share (EPS)
4.11
TTM Avg
4.00
3Y Avg
3.51
5Y Avg
2.55
Market Cap
$24.30B
Earnings Per Share (EPS)
-7.76
TTM Avg
-4.08
3Y Avg
9.21
5Y Avg
14.48
Market Cap
$24.37B
Earnings Per Share (EPS)
7.82
TTM Avg
6.79
3Y Avg
7.36
5Y Avg
7.17
Market Cap
$24.62B
Earnings Per Share (EPS)
7.85
TTM Avg
3.38
3Y Avg
2.74
5Y Avg
2.31
Market Cap
$25.55B
Earnings Per Share (EPS)
12.09
TTM Avg
9.71
3Y Avg
9.57
5Y Avg
13.14
Market Cap
$16.40B
Earnings Per Share (EPS)
17.07
TTM Avg
14.35
3Y Avg
11.37
5Y Avg
9.10
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $21.10B | 27.91 | 28.29 | 23.40 | 19.31 |
| STERIS plc (STE)vs › | $20.54B | 8.18 | 7.08 | 4.77 | 4.37 |
| Viatris Inc. (VTRS)vs › | $19.23B | -0.36 | -1.77 | -0.44 | -0.66 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 4.11 | 4.00 | 3.51 | 2.55 |
| BioNTech SE (BNTX)vs › | $24.30B | -7.76 | -4.08 | 9.21 | 14.48 |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.37B | 7.82 | 6.79 | 7.36 | 7.17 |
| Incyte Corporation (INCY)vs › | $24.62B | 7.85 | 3.38 | 2.74 | 2.31 |
| Labcorp Holdings Inc. (LH)vs › | $25.55B | 12.09 | 9.71 | 9.57 | 13.14 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 17.07 | 14.35 | 11.37 | 9.10 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.94B | 9.42 | 8.33 | 8.09 | 9.83 |
Trailing EPS (TTM)
$27.91
Forward EPS (Est.)
$26.15
P/E Ratio
17.8
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 30.13 |
| 2024-12-31 | 26.44 |
| 2023-12-31 | 21.04 |
| 2022-12-31 | 15.98 |
| 2021-12-31 | 10.60 |
| 2020-12-31 | 11.65 |
| 2019-12-31 | -2.39 |
| 2018-12-31 | 13.54 |
| 2017-12-31 | 9.50 |
| 2016-12-31 | 16.29 |
| 2015-12-31 | 14.17 |
| 2014-12-31 | 7.06 |
| 2013-12-31 | 3.49 |
| 2012-12-31 | 5.84 |
| 2011-12-31 | 3.81 |
| 2010-12-31 | 1.89 |
| 2009-12-31 | 0.37 |
| 2008-12-31 | -0.93 |
| 2007-12-31 | 0.47 |
| 2006-12-31 | 1.61 |
| 2005-12-31 | 1.43 |
| 2004-12-31 | 0.36 |
| 2003-12-31 | -0.24 |
| 2002-12-31 | -0.57 |
| 2001-12-31 | -0.92 |
| 2000-12-31 | -1.97 |
| 1999-12-31 | -1.26 |
| 1998-12-31 | -0.77 |
